Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2020 | Refractory multiple myeloma: analyzing MAMMOTH and STORM

Luciano Costa • 3 Oct 2020
COMy 2020
Multiple Myeloma Daratumumab Selinexor
MAMMOTH STORM

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the MAMMOTH and STORM (NCT02336815) studies evaluating selinexor in refractory myeloma. The efficacy of selinexor in combination with low-dose dexamethasone was demonstrated in the pivotal Phase 2 STORM study (NCT02336815). The results of the MAMMOTH study have been used as a benchmark to refer to. Analysis of the MAMMOTH population and the STORM population saw an improvement in overall survival with selinexor in refractory patients. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.

Disclosures

Research support : Amgen, Janssen
Honorarium: BMS, Janssen, Amgen, Genentech, Astra Zeneca

More from Luciano Costa

1:45
Challenges for community clinicians treating multiple myeloma
Luciano Costa • 11 Dec 2023
2:02
Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma
Luciano Costa • 11 Dec 2023
2:40
Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myeloma
Luciano Costa • 11 Dec 2023
3:38
Outcomes for patients with multiple myeloma who have had first-line monoclonal antibody exposure
Luciano Costa • 11 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals